Mignini Irene, Galasso Linda, Piccirilli Giulia, Calvez Valentin, Termite Fabrizio, Esposto Giorgio, Borriello Raffaele, Miele Luca, Ainora Maria Elena, Gasbarrini Antonio, Zocco Maria Assunta
CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy.
Antioxidants (Basel). 2024 Dec 14;13(12):1532. doi: 10.3390/antiox13121532.
Oxidative stress has been described as one of the main drivers of intracellular damage and metabolic disorders leading to metabolic syndrome, a major health problem worldwide. In particular, free radicals alter lipid metabolism and promote lipid accumulation in the liver, existing in the hepatic facet of metabolic syndrome, the metabolic dysfunction-associated steatotic liver disease (MASLD). Recent literature has highlighted how nicotine, especially if associated with a high-fat diet, exerts a negative effect on the induction and progression of MASLD by upregulating inflammation and increasing oxidative stress, abdominal fat lipolysis, and hepatic lipogenesis. Moreover, considerable evidence shows the central role of intestinal dysbiosis in the pathogenesis of MASLD and the impact of nicotine-induced oxidative stress on the gut microbiome. This results in an intricate network in which oxidative stress stands at the intersection point between gut microbiome, nicotine, and MASLD. The aim of this review is to delve into the molecular mechanisms linking tobacco smoking and MASLD, focusing on nicotine-induced microbiota modifications and their impact on MASLD development.
氧化应激被认为是导致细胞内损伤和代谢紊乱的主要驱动因素之一,而这些损伤和紊乱会引发代谢综合征,这是一个全球性的重大健康问题。特别是,自由基会改变脂质代谢并促进肝脏中的脂质积累,这在代谢综合征的肝脏方面即代谢功能障碍相关脂肪性肝病(MASLD)中存在。最近的文献强调了尼古丁,尤其是与高脂肪饮食相关联时,如何通过上调炎症反应、增加氧化应激、腹部脂肪分解和肝脏脂肪生成,对MASLD的诱导和进展产生负面影响。此外,大量证据表明肠道微生物群失调在MASLD发病机制中的核心作用以及尼古丁诱导的氧化应激对肠道微生物组的影响。这导致了一个复杂的网络,其中氧化应激处于肠道微生物组、尼古丁和MASLD的交叉点。本综述的目的是深入探讨吸烟与MASLD之间的分子机制,重点关注尼古丁诱导的微生物群改变及其对MASLD发展的影响。
Antioxidants (Basel). 2024-12-14
Antioxidants (Basel). 2024-11-14
Antioxidants (Basel). 2025-1-6
Hepatol Commun. 2025-9-5
Gastro Hep Adv. 2023-10-6
Metabolites. 2024-6-28
Int J Mol Sci. 2024-7-5